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linezolid in the empiric treatment of nosocomial pneumonias incor-
porating results from a recent prospective, double-blind, multicenter,
controlled trial in adults with suspected methicillin-resistant Staph-
ylococcus aureus (MRSA) nosocomial pneumonia.Methods: A decision-
analytic model examining the cost-effectiveness of linezolid versus
vancomycin for the empiric treatment of nosocomial pneumonia was
created. Publicly available cost, efﬁcacy, and utility data populated
relevant model variables. A probabilistic sensitivity analysis varied
parameters in 10,000 Monte-Carlo simulations, and univariate sensi-
tivity analyses assessed the impact of model uncertainties and the
robustness of our conclusions. Results: Results indicated that the cost
per quality-adjusted life-year (QALY) increased 6% ($22,594 vs.
$23,860) by using linezolid versus vancomycin for nosocomial pneu-
monia. The incremental cost per QALY gained by using linezolid overee front matter Copyright & 2015, International S
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Ann Arbor, MI 48106.vancomycin was $6,089, and the incremental cost per life saved was
$68,615 with the use of linezolid. Vancomycin dominated linezolid in
the subset of patients with documented MRSA. The incremental cost
per QALY gained using linezolid if no mortality beneﬁt exists between
agents or a 60-day time horizon was analyzed was $19,608,688 and
$443,662, respectively. Conclusions: Linezolid may be a cost-effective
alternative to vancomycin in the empiric treatment of patients with
suspected MRSA nosocomial pneumonia; however, results of our
model were highly variable on a number of important variables and
assumptions including mortality differences and time frame
analyzed.
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Nosocomial pneumonia accounts for about 15% of hospital-
acquired infections, making it the third most common nosoco-
mial infection in the United States [1]. Nosocomial pneumonias
also contribute to increased costs between $11,897 and $25,072
per incident and are a leading cause of death among all nosoco-
mial infections [1–3]. Historically, gram-negative bacteria have
been associated with most of the nosocomial pneumonias;
however, gram-positive organisms have become an increasing
concern. The National Nosocomial Infections Surveillance study
found that Staphylococcus aureus is the cause of 17% of all
nosocomial pneumonias [4]. Antimicrobial treatment options
for suspected or conﬁrmed gram-positive organisms, including
methicillin-resistant Staphylococcus aureus (MRSA), are rather
limited. The 2005 American Thoracic Society/Infectious Diseases
Society of America guidelines recommend both vancomycin and
linezolid as suitable options for the treatment of nosocomial
pneumonia [5]. Several published reports report higher survivaland clinical cure rates with linezolid than with vancomycin for
the treatment of nosocomial pneumonia; however, the method-
ology and results of these post hoc analyses are controversial for
a number of reasons including their retrospective nature, dosing
of vancomycin, and inclusion of patients with methicillin-
susceptible S. aureus [6–11]. As a result, no clear preference
between agents is speciﬁed and international guidelines fail to
delineate a primary treatment recommendation [5,11].
To overcome shortcomings of previous trials, Wunderink et al.
[12] recently published results of their prospective, double-blind,
multicenter, controlled trial in adults with MRSA nosocomial
pneumonia. This study, also known as the ZEPHyR trial,
attempted to alleviate the controversy of previous studies and
prospectively assess the comparative efﬁcacy between linezolid
and vancomycin for the treatment of proven MRSA nosocomial
pneumonia. Patients treated with linezolid experienced signiﬁ-
cantly higher clinical response at the end of the study in the per-
protocol patient populations and 60-day mortality was similar
between groups [12].ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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zolid and vancomycin. In lieu of this fact, results of the ZEPHyR
trial warrant further examination of cost-effective antimicrobial
options for the treatment of nosocomial pneumonia. Several
cost-effectiveness studies comparing linezolid and vancomycin
for the treatment of various pneumonias exist in the literature.
These analyses use data published before the ZEPHyR trial and
generally favor linezolid. Shorr et al. [13] reported a cost per
quality-adjusted life-year (QALY) gained of $29,945 with line-
zolid in patients with ventilator-associated pneumonia.
Machado et al. [14] also reported an advantage for linezolid
versus vancomycin in treating ventilator-associated pneumonia
caused by MRSA using clinical cure rates of 62.2% versus 21.2%
for MRSA-ventilator-associated pneumonia. They calculated
that linezolid is 200% more efﬁcacious than vancomycin and
results in a cost reduction of $3512 per cured patient. De Cock
et al. [15] analyzed linezolid versus vancomycin in patients with
nosocomial pneumonia from the perspective of the German
health care system and reported 2.3 life-years gained per
linezolid-treated patient and an incremental cost of $683 per
treatment episode.
Three recent cost-effectiveness analyses build on this work
incorporating results from the ZEPHyR trial. Using a 4-week
decision tree model, Patel et al. [16,17] found that linezolid
dominated vancomycin in patients with conﬁrmed MRSA noso-
comial pneumonia in both the United States and Germany.
Niederman et al. [18] performed a post hoc piggyback cost-
effectiveness analysis and found an incremental cost-
effectiveness ratio of $16,561 for linezolid per treatment success.
In the aforementioned studies, empiric antimicrobial treat-
ment and the costs and adverse events associated with its use
before conﬁrmation of MRSA were not considered. These are
relevant and important considerations in day-to-day clinical
practice in which therapy is often initiated and continued with-
out the beneﬁt of pathogen identiﬁcation to guide antimicrobial
therapy. To our knowledge, the cost-effectiveness of treating
nosocomial pneumonias that consider the empiric treatment
phase along with quality-of-life beneﬁts from adverse eventFig. 1 – Decision tree comparing empiric treatment strategies in
methicillin-resistant Staphylococcus aureus.avoidance and analyze mortality differences reported in the
ZEPHyR trial has not been determined. We undertook an analysis
to evaluate the cost-effectiveness of vancomycin versus linezolid
in the empiric treatment of nosocomial pneumonias incorporat-
ing results from the ZEPHyR trial.Methods
A decision-analytic model was developed comparing linezolid
versus vancomycin for the treatment of nosocomial pneumonia
in a hypothetical cohort of adult patients with radiographic
documentation and relevant signs and symptoms of nosocomial
pneumonia (Fig. 1). The model was developed from a payer
perspective in the United States and created using decision
analysis software (DATA, TreeAge Software, Inc., Williamstown,
MA). The primary outcome measure was incremental cost per
QALY gained, with secondary analyses on incremental cost per
life saved. Multiple univariate sensitivity analyses assessed the
impact of model uncertainties and the robustness of our analysis.
In addition, we undertook a probabilistic sensitivity analysis by
varying parameters in 10,000 Monte-Carlo simulations.
Patients were initiated on either vancomycin or linezolid. All
model variables are reported in Table 1. We assumed medication
dosing in patients with normal weight and renal function (i.e.,
vancomycin 1 g twice daily and linezolid 600 mg twice daily).
Fluctuations in vancomycin dosing for weight and renal function
were accounted for by varying the acquisition cost of vancomycin
across a spectrum of likely scenarios in the sensitivity analyses.
All patients received 3 days of therapy until culture results
returned. To accurately replicate real-life clinical practice, we
estimated that 50% of the patients would continue to receive
gram-positive coverage if MRSA was not identiﬁed. The incidence
of MRSA isolation and duration of antimicrobial therapy matched
reports in the ZEPHyR trial and were varied in our sensitivity
analyses [12]. Patients initiated on vancomycin received a single
vancomycin trough level during empiric treatment and a second
if vancomycin was continued for a treatment course. Patients notpatients with suspected nosocomial pneumonias. MRSA,
Table 1 – Decision-analytic model variables.
Variable Base-case value Range Distribution
Costs
Medication cost/d [37]
Vancomycin $27 5–100 Normal (27  2)
Linezolid
IV $246 100–246 Gamma (246  20)
PO $304 100–304 Gamma (304  20
Vancomycin assay* $10 0–100 Normal (10  5)
Attributable cost
Pneumonia [3,19] $20,910 10,000–30,000 Normal (20,910  2,091)
Nephrotoxicity [19,26] $14,386 10,000–45,000 Normal (14,386  1,439
Thrombocytopenia [19,27] $17,860 5,000–25,000 Normal (17,860  3,500)
Probabilities
Survival [12]
Base case (ITT population)
Vancomycin 0.83 0.5–1 Beta (0.83  0.01)
Linezolid 0.843 0.5–1 Beta (0.843  0.01)
mITT population
Vancomycin 0.737 0.5–1 Beta (0.737  0.005)
Linezolid 0.719 0.5–1 Beta (0.719  0.005)
MRSA identiﬁed [12] 0.38 0.25–0.75 Normal (0.38  0.05)
MRSA coverage continued when culture negative* 0.5 0–1 Normal (0.5  0.1)
Nephrotoxicity [12]
Base case (ITT population)
Vancomycin 0.073 0–0.2 Beta (0.073  0.01)
Linezolid 0.037 0–0.2 Beta (0.037  0.01)
mITT population
Vancomycin 0.182 0–0.2 Beta (0.182  0.01)
Linezolid 0.084 0–0.2 Beta (0.084  0.01)
Thrombocytopenia [12]
Base case (ITT population)
Vancomycin 0.022 0–0.3 Beta (0.022  0.001)
Linezolid 0.013 0–0.3 Beta (0.013  0.001)
mITT population
Vancomycin 0.132 0–0.3 Beta (0.132  0.01)
Linezolid 0.163 0–0.3 Beta (0.163  0.01)
Therapy change
Base case (ITT population)
Vancomycin 0.012 0–0.5 Beta (0.012  0.001)
Linezolid 0.007 0–0.5 Beta (0.006  0.001)
mITT population
Vancomycin 0.029 0–0.5 Beta (0.029  0.01)
Linezolid 0.017 0–0.5 Beta (0.017  0.01)
Utilities
Survival QALY [13,20] 0.92 0.8–1 NA
Nephrotoxicity QALY [28,29] 0.7 0–1 NA
Profound nephrotoxicity QALY [28,29] 0.6 0–1 NA
Thrombocytopenia QALY [30,31] 0.76 0–1 NA
Days of adverse event* 10 1–60 Normal (10  2)
Treatment days [12] 13 8–21 Normal (13  2)
Days IV linezolid* 7 0–21 Normal (7  2)
Days until susceptibilities return* 3 2–5 Normal (3  0.5)
Days of new treatment if therapy change* 7 0–14 Normal (7  1)
Years of survival [20,21] 15 0–50 Normal (11  2.7)
Discount rate 0.03 0–6 NA
ITT, intent-to-treat; IV, intravenous; mITT, modiﬁed intent-to-treat; MRSA, methicillin-resistant Staphylococcus aureus; NA, not applicable/
available; PO, per os (by mouth); QALY, quality-adjusted life-year.
* Expert opinion.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 6 1 4 – 6 2 1616requiring a therapy change continued on initial therapy for their
entire treatment course, and mortality was assessed at 60 days. A
percentage of patients matching those who discontinued initial
treatment in the ZEPHyR trial were changed to alternativetherapy. Patients initiated on linezolid who required a therapy
change were changed to vancomycin after 6 days of therapy in
our base case. Likewise, patients initiated on vancomycin were
given linezolid for their remaining course. The rates of therapy
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 6 1 4 – 6 2 1 617changes and the duration of the initial course before a therapy
change were varied in our sensitivity analyses.
We incorporated previously reported nosocomial pneumonia
economic modeling techniques to populate inpatient costs, long-
term survival, and health-utility information [13]. We populated
clinical variables such as mortality and adverse events from
results reported in the intent-to-treat (ITT) population in the
ZEPHyR trial [12]. The ITT population was chosen for our base-
case analysis because we felt that this population, in which
antimicrobial therapy was started empirically before MRSA con-
ﬁrmation, most accurately represented choices faced by practi-
tioners in their day-to-day practice environment.
Wunderink et al. [12] showed a nonstatistically signiﬁcant all-
cause 60-day mortality of 15.7% for linezolid and 17% for vanco-
mycin in the ITT population, and 28.1% and 26.3%, respectively,
in the modiﬁed ITT (mITT) population (i.e., patients with con-
ﬁrmed MRSA pneumonia). Mortality in the per-protocol popula-
tion was not reported. Conversely, 60-day survival favored
vancomycin in the mITT population. This contrast between study
groups is an important consideration investigated as part of our
secondary analysis of patients in the mITT population. Non-
statistically signiﬁcant variations in length of stay, intensive care
unit cost per day, and mechanical ventilation were reported by
Niederman et al. [18] in their post hoc analysis of patients with
conﬁrmed MRSA nosocomial pneumonia. We accounted for this
variation by assessing a 4% increase in the overall cost of
inpatient stay to patients initiated on vancomycin in our mITT
analyses. Auxiliary costs associated with the primary treatment
of nosocomial pneumonia were equivalent in our base case, and
a threshold analysis on this variable was conducted in the
sensitivity analysis. We also analyzed results when survival rates
between treatment arms were considered an equivalent 84% in
the ITT population and 73% in the mITT population.
The wholesale acquisition cost of linezolid and vancomycin
was used, and pricing decreases and advantageous pricing
incentives were accounted for in sensitivity analyses. The incre-
mental cost of pneumonia treatment was determined from a
study published by Warren et al. [3]. We excluded the cost of
antimicrobial therapy from their reported results and adjusted
for inﬂation to 2014 US dollars [3,19]. Posthospitalization life
expectancy data were obtained from published reports involving
severe sepsis [20]. We estimated that the average age of patients
in our model was 61 years, and reports have suggested that the
life expectancy of patients who develop severe sepsis is
decreased from baseline [21]. Thus, we predicted that each addi-
tional year of survival would generate 0.92 QALY. Unlike the
analysis by Shorr et al. [13], which further reduced the utility
measure to 0.83, we maintained a point estimate of 0.92 in an
attempt to account for the uncertainty in utility estimates
between respiratory failure or mechanical ventilation and noso-
comial pneumonia. We predicted that survivors would live 15
additional years after the development of nosocomial pneumonia
[22,23]. In addition to this, a secondary analysis assuming a
limited 60-day time horizon was performed. This time horizon
matches the all-cause mortality review period reported in the
ZEPHyR trial [12]. All additional utility and cost measures were
discounted at a rate of 3% and adjusted for inﬂation to 2014 US
dollars [19].
Nephrotoxicity and thrombocytopenia are suspected or
known events associated with the use of vancomycin and line-
zolid, respectively. Results of several nosocomial pneumonia
meta-analysis showed no signiﬁcant difference in nephrotoxicity
between agents; however, these studies did not include informa-
tion from the ZEPHyR trial [12,23–25]. A recent meta-analysis by
Jiang et al. [23] showed a higher rate of renal dysfunction
(Relative Risk ¼ 0.41; 95% conﬁdence interval ¼ 0.27–0.64; P o
0.0001) with glycopeptide antibiotics. We chose to include theactual nonstatistically signiﬁcant incidence of both nephrotox-
icity and thrombocytopenia from the ZEPHyR trial in our base-
case analysis. Renal failure, deﬁned as a 0.5 mg/dL increase in
serum creatinine level if normal at baseline or a 50% increase if
abnormal at baseline, was reported as a treatment-related
adverse event in both patients initiated on linezolid and patients
initiated on vancomycin (3.7% vs. 7%) in the ITT population,
whereas thrombocytopenia (platelet count o150,000 platelets/
mm3 if normal at baseline; 50% decrease if low at baseline)
occurred in 1.3% of the patients initiated on linezolid and 2.2%
of the patients initiated on vancomycin [12]. The incremental
cost of treating treatment-induced nephrotoxicity and thrombo-
cytopenia was based on published literature reports [19,26,27].
We assumed that patients with a treatment-related adverse
event would experience a corresponding short-term decrease in
their quality of life. Patients with these adverse events were
assigned a utility estimate corresponding to nephrotoxicity or
thrombocytopenia [28–31]. Although it is not reported in the
clinical trial, we assumed that 3% of nephrotoxicity would be
profound, deﬁned as an increase in serum creatinine by 50% to a
minimum peak of 2.0 mg/dL [32]. The thrombocytopenia utility
was obtained from the mean of patients experiencing thrombo-
cytopenia without major bleeding or hemorrhagic stroke [30,31].
These mean costs and utilities were attributed to the subset of
patients who developed subsequent treatment-related adverse
events.Results
Results of our base-case analysis showed that patients initiated
on linezolid experienced a treatment cost increase of 6% ($22,594
vs. $23,486) while also gaining an additional 0.15 QALY. The
incremental cost per QALY gained by using linezolid instead of
vancomycin was $6089 (Table 2). Our model also predicted an
incremental cost per life saved of $68,615 by using linezolid in
favor of vancomycin.
As expected, survival rates for vancomycin or linezolid had
the potential to affect results based on a willingness-to-pay
threshold of $100,000/QALY (Fig. 2). Vancomycin became the
preferred alternative when the vancomycin treatment survival
rate increased from 83% to 84.2% whereas the survival rate for
linezolid remained 84.3%. Likewise, vancomycin became a more
cost-effective option when the survival rate for linezolid
decreased from 84.3% to 83.1% and that for vancomycin remained
83%. Linezolid was also no longer cost-effective if the estimated
lifetime survival after successful treatment was less than 0.6
years. No other variable, including medication acquisition cost,
treatment duration, probability of continuing treatment if MRSA
was not identiﬁed, the incidence of therapy changes, or the cost
or utilities of adverse events, affected base-case results.
Survival rates, the cost of linezolid, the cost of nephrotoxicity,
and the rate of conversion to oral linezolid affected results when
we examined the sensitivity of our model at a willingness-to-pay
threshold of $50,000/QALY. Linezolid was not cost-effective at
this threshold when the survival rate for either linezolid or
vancomycin decreased by 1.1% or increased by 1% from baseline
while the competing alternative remained at baseline. The only
other variable to affect results was the estimated lifetime sur-
vival. Linezolid was not cost-effective if survival was less than 1.5
years.
Results of the probabilistic sensitivity analysis demonstrated
a 78% chance that linezolid would be cost-effective at a
willingness-to-pay threshold of $100,000. When the willingness-
to-pay threshold was varied between $50,000 and $150,000, line-
zolid was cost-effective between 72.1% and 79.7% of the time
(Fig. 3).
Table 2 – C/E of nosocomial pneumonia treatment strategies.
Strategy* Cost
($)
Incremental
cost ($)
Effect† Incremental
effect
Incremental
C/E (ICER) ($)
Base case (ITT population)
Cost/QALY (QALY) (QALY)
Vancomycin 22,594 9.35
Linezolid 23,486 892 9.5 0.15 6,089
Cost/life saved (Survival %) (Survival %)
Vancomycin 22,594 83
Linezolid 23,486 892 84.3 1.3 68,615
mITT subgroup analysis (i.e., patients with documented MRSA)
Cost/QALY (QALY) (QALY)
Vancomycin 27,057 8.3
Linezolid 27,334 278 8.1 –0.2 Dominated
Cost/life saved (Survival %) (Survival %)
Vancomycin 27,057 73.7
Linezolid 27,334 278 71.9 –1.8 Dominated
60-d time horizon analysis
Cost/QALY (ITT population) (QALY) (QALY)
Vancomycin 22,594 0.13
Linezolid 23,486 892 0.13 0.00 443,662
Cost/QALY (mITT population) (QALY) (QALY)
Vancomycin 27,057 0.11
Linezolid 27,334 278 0.11 –0.00 Dominated
Equivalent mortality analysis (adverse event differences only)
Cost/QALY (ITT population) (QALY) (QALY)
Vancomycin 22,594 9.5
Linezolid 23,486 892 9.5 0.00 19,608,688
Cost/QALY (mITT population) (QALY) (QALY)
Vancomycin 27,057 8.2
Linezolid 27,334 278 8.2 0.00 4,128,049
C/E, cost-effectiveness; ICER, incremental cost-effectiveness ratio; ITT, intention-to-treat; mITT, modiﬁed intent-to-treat; MRSA, methicillin-
resistant Staphylococcus aureus; QALY, quality-adjusted life-year.
* Calculations for C/E were performed by taking the incremental cost (difference between costs of compared strategies) divided by the
incremental effectiveness (difference between the effectiveness of the compared strategies).
† QALY differences may not be apparent as expressed because of rounding.
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reported in the mITT populations (i.e., patients with documented
MRSA) likely because of a higher incidence of survival reported in
the vancomycin population. Vancomycin dominated linezolid in
this subset of patients by displaying both decreased treatment
costs with increased effectiveness. Linezolid (473.7%) and van-
comycin (o71.9%) survival rates affected results in the sensitivity
analysis. As with the ITT population, the model was robust to all
other variables. Vancomycin displayed a greater than 99% chance
of cost-effectiveness at willingness-to-pay thresholds of $50,000,
$100,000, and $150,000.
When we used a 60-day time horizon, the incremental cost
per QALY gained with linezolid use increased to $443,662 in the
ITT population, and vancomycin dominated linezolid in the mITT
population. This analysis was again sensitive to variations in
survival rates. A decrease in vancomycin survival rate from 83%
to 78.4% or lower and an increase in linezolid survival rate from
84.3% to 88.9% made linezolid cost-effective at a willingness-to-
pay threshold of $100,000 per QALY gained. A decrease in the
daily cost of intravenous linezolid to $176 also affected results in
favor of linezolid in the ITT analysis. A number of variables had
the potential to shift results in favor of linezolid in the mITT
population. Variations in linezolid (475.5%) and vancomycin
(o70.1%) survival rates, the cost of intravenous linezolid (o
$203), the rates of vancomycin therapy change (438.3%), the costof nephrotoxicity (4$19,925), and nephrotoxicity rates (421.9%
for vancomycin and o4.7% linezolid) all affected results in
linezolid’s favor.
The incremental cost of using linezolid as the preferred
treatment option without any mortality beneﬁt between agents
was an additional $892 per patient in the ITT population and $278
in the mITT population. There were QALY gains for linezolid due
to overall decreased antimicrobial-related adverse events in both
study populations. The incremental cost per QALY gained for
linezolid with equivalent mortality was $19,608,688 in the ITT
group and $4,128,049 in patients with conﬁrmed MRSA. At our
willingness-to-pay threshold, the ITT group model was sensitive
to the incidence of vancomycin-induced nephrotoxicity (413.4%)
and thrombocytopenia (47.1%), whereas the mITT group was
affected by changes in linezolid- and vancomycin-induced neph-
rotoxicity of less than 6.5% and more than 20.1%, respectively,
from baseline.Discussion
Health care systems and payers have the responsibility to
balance cost-effective therapies with good patient outcomes.
Our base-case analysis demonstrated that linezolid was deter-
mined to be cost-effective on the basis of commonly used
Fig. 2 – Sensitivity analysis comparing linezolid versus vancomycin across 10,000 simulations at varying probabilities of
survival. Base-case mortality assumptions represented corresponding axis. WTP, willingness to pay.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 6 1 4 – 6 2 1 619willingness-to-pay thresholds; however, base-case results did not
tell the entire story. Our model was sensitive to changes in
mortality, the patient population, and the study time horizon. If
we did not use a lifetime time horizon, if there was no mortality
difference between agents, or if used in patients with docu-
mented MRSA, linezolid was either dominated by vancomycinFig. 3 – Acceptability curve of linezolid versus vancomycin for the
fraction of the time linezolid or vancomycin was cost-effective a
Monte-Carlo simulations. QALY, quality-adjusted life-year.or substantially not cost-effective. Ultimately, the determination
of whether to use vancomycin or linezolid in the empiric treat-
ment of nosocomial pneumonia depends on the tolerance and
willingness-to-pay threshold of decision makers.
Our model also contained several limitations of note. First, the
ZEPHyR trial, on which our analysis was primarily based,treatment of nosocomial pneumonias. This ﬁgure shows the
t various willingness-to-pay-per-QALY thresholds in 10,000
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patients requiring mechanical ventilation, the number of patients
with bacteremia and pre-existing kidney disease, and suboptimal
vancomycin dosing [6]. All these trial limitations favored linezolid
and likely affected results to the same degree that results were
affected in the ZEPHyR trial. Our base-case model did not account
for the signiﬁcant variations in clinical success reported in the
ZEPHyR trial. Increased utilization of health care resources may
have occurred in patients with lower response rates to initial
therapy. We attempted to account for reports of nonsigniﬁcant
variations in resource use in ourmITT population; however, similar
literature reports in our base-case population are lacking [18]. A
univariate sensitivity analysis showed that an 11.2% overall cost
increase due to the increased cost of the lack of clinical success
would be required to provide cost neutrality between treatments.
In addition, our base-case model used a lifetime time horizon
whenWunderink et al. [12] reported survival only through 60 days.
As such, we used population estimates for survival and quality of
life after the time period reported in the clinical trial. Actual
resource utilization both during and after the ZEPHyR trial (e.g.,
number of chest x-rays, increased costs due to lack of clinical
success, and ventilator days) may have varied between groups. We
attempted to account for this limitation by incorporating wide
ranges on these variables in our sensitivity analyses and by
performing a secondary analysis using a 60-day study time period.
Of note, although linezolid was not cost-effective in this 60-day
analysis, a decrease in the cost of linezolid had the potential to
change results. This was the only scenario analyzed in which
medication cost had the potential to change results. This is
noteworthy because linezolid has recently obtained generic status
in the United States and pricing decreases should follow.
Although mortality differences were reported in both the
mITT and ITT populations, neither reached statistical signiﬁ-
cance. International good practice guidelines for decision-
analytic modeling suggest that results should not be rejected
solely because they do not reach generally accepted probability
thresholds [33]. As such, we reported and analyzed outcomes
from both populations and also analyzed results when a mortal-
ity difference did not exist. Linezolid’s advantage in our base-case
model stemmed primarily from a nonsigniﬁcant 60-day survival
beneﬁt seen in the ZEPHyR trial’s ITT population. When our
perspective shifted to patients with documented MRSA nosoco-
mial pneumonia, the advantage was decidedly in vancomycin’s
favor due to lower overall treatment costs and improved rates of
survival described previously [12]. Results of the ZEPHyR trial may
suggest that linezolid is a more effective agent for the treatment
of nosocomial pneumonias, perhaps due to increased activity
and statistically signiﬁcant greater clinical success against MRSA
pneumonias. Actual results reported in patients with docu-
mented MRSA pneumonias and used in our model showed that
fewer patients died when vancomycin, rather than linezolid, was
used in patients with documented MRSA pneumonias. Small
changes in mortality in either direction had the potential to
affect results. If there is no survival advantage between agents, as
Wunderink et al. [12] acknowledged in their discussion, the costs
to health systems and third-party payers by primarily using
linezolid in this patient population could increase, though the
increase was a minor percentage of overall treatment costs. The
great discrepancy in medication cost was minimized in our
model by reduced costs associated with the treatment of adverse
events induced by antimicrobial therapy. These results appear to
support other recent cost-effectiveness analyses in patients with
conﬁrmed MRSA nosocomial pneumonia [16–18].
We did not investigate the impact of adverse events other
than nephrotoxicity or thrombocytopenia. The incidence of
thrombocytopenia, an adverse event commonly associated with
the use of linezolid, was higher in patients treated withvancomycin (1.3% vs. 2.2%) [12]. A recent meta-analysis incorpo-
rating results of the ZEPHyR trial reported that statistically
signiﬁcant differences in the rates of rash and renal dysfunction
were higher with glycopeptide antibiotics [22]. The authors found
no difference in thrombocytopenia and attributed this to the time-
dependent nature of thrombocytopenia, which may not manifest
itself in the relatively short treatment durations of pneumonia.
Excluding the incidence and cost of hypersensitivity reactions
from the ZEPHyR trial and including thrombocytopenia may have
biased results slightly in favor of and against vancomycin, respec-
tively. Results of our base case did not change when we analyzed
thrombocytopenia or nephrotoxicity rates and utilities as reported,
when no difference was assumed, or when these adverse events
were excluded from our analysis entirely. Given the wide varia-
tions in the cost of adverse events in our sensitivity analysis and
the robustness of these indicators, it is unlikely that the inclusion
of additional adverse events would have affected results.
The cost of medication preparation and distribution (i.e.,
intravenous solutions and nursing and pharmacy labor costs)
was not included. We felt that these costs were ﬁxed and would
not signiﬁcantly affect results. We intentionally set the vanco-
mycin sensitivity range high to capture these added costs. Our
base-case vancomycin dose is a low estimate in many patients
with good renal function and increased body weight, and too high
for patients with renal dysfunction or the elderly. The wide
sensitivity range accounted for all likely vancomycin dosing
weights and renal function. No variation in the cost or dosing
regimen of vancomycin within our predeﬁned sensitivity range
had the potential to affect results. Likewise, we did not include
the additional cost of gram-negative pathogen coverage in our
model because utilization would be similar between treatment
arms and unlikely to affect overall results.
International guidelines recommend broad empiric coverage
including either linezolid or vancomycin with an eye on dees-
calating therapy if MRSA is not identiﬁed [5]. Surprisingly, the
effectiveness of de-escalation when cultures are negative did not
affect results. This suggests that results may be generalizable
with limited formal de-escalation protocols, rapid diagnostic
technology, or sustained antimicrobial stewardship efforts.
Finally, we did not address the consequence of increasing S.
aureus resistance. In addition to negative patient outcomes, resist-
ant organisms are associated with increased costs. Linezolid-
resistant Staphylococcus isolates have been reported and reduced
susceptibility to vancomycin is a concern [34]. To date, we are
unaware of reports of vancomycin-intermediate or vancomycin-
resistant S. aureus pneumonia, whereas linezolid-resistant S.
aureus pneumonia has been reported in the literature [35,36].
Increased utilization of linezolid through increased empiric uti-
lization in patients with suspected nosocomial pneumonias will
most likely lead to increased linezolid resistance. The loss or
decline in linezolid activity is particularly concerning given that it
is often conserved for a spectrum of multidrug-resistant organ-
isms. We encourage clinicians and decision makers to consider
this important point along with the existing clinical and economic
data when assessing empiric pneumonia treatment regimens. Not
including the cost in treating resistant infections or the societal
cost of advancing antimicrobial resistance is an acknowledged
limitation and we encourage further research in this area.
In summary, results of our model were highly variable on the
basis of a number of key variables and assumptions, including
whether there was a mortality difference between agents and in
the time frame analyzed. In nearly all the scenarios investigated, the
noteworthy difference in medication cost was offset to varying
degrees by lower overall costs associated with the treatment of
adverse events induced by antimicrobial therapy. If a mortality
difference exists between agents and we consider a lifetime time
horizon, empiric utilization of linezolid may be a cost-effective
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 6 1 4 – 6 2 1 621alternative to vancomycin. If no mortality difference existed between
agents, a shorter time period was considered, or linezolid was used
in a subset of patients with documented MRSA, then the results
shifted, inmost cases in favor of vancomycin. Results of our analysis,
and our discussion of the limitations herein, can provide clinicians,
patients, or other stakeholders a multifactorial cost framework to
further facilitate discussions when evaluating antimicrobial therapy
for the empiric treatment of nosocomial pneumonia.
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